<DOC>
	<DOCNO>NCT00024687</DOCNO>
	<brief_summary>Although Neopharm terminate sponsorship study , continue sponsorship NCI . Please contact Raffit Hassan , MD 301-451-8742 information . Also see related NCI study `` Experimental Drug SS1 ( dsFv ) -PE38 Treat Cancer '' ( Study ID number 010011 ) . SS1 ( dsFv ) -PE38 oncology drug product contain bacteria toxin , fuse high affinity , disulfide stabilize antibody . The fused protein retain cell kill activity , bind cell express mesothelin . Tumors characterize high surface mesothelin expression include mesothelioma ; epithelial carcinoma ovary peritoneum ; squamous cancer cervix upper aerodigestive tract , include esophagus , head , neck cancer . This dose-escalating study determine maximum tolerate dose ( MTD ) intravenous SS1 ( dsFv ) -PE38 administer every day six dos . Dose escalation proceed cohort 3 dose-limiting toxicity ( DLT ) observe .</brief_summary>
	<brief_title>Study SS1 ( dsFv ) -PE38 ( SS1P ) Anti-Mesothelin Immunotoxin Advanced Malignancies : IV Infusion QOD x Six Doses</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicities maximum tolerate dose ( MTD ) six dos SS1 ( dsFv ) -PE38 QOD administer intravenous infusion patient advanced malignancy . II . Characterize plasma pharmacokinetics SS1 ( dsFv ) -PE38 intravenous infusion . III . Determine toxicities attributable subsequent course SS1 ( dsFv ) -PE38 . IV . Evaluate response select advanced malignancy intravenous infusion six dos SS1 ( dsFv ) -PE38 QOD administer MTD . V. Determine induction antibody SS1 ( dsFv ) -PE38 relationship pharmacokinetics . PROTOCOL OUTLINE : To exclude immediate allergic hypersensitivity reaction , patient receive test dose SS1 ( dsFv ) -PE38 , observe 30 minute prior receive study dose . Each treatment give intravenous infusion 30 minute every day . Hydration maintain . ( Oral hydration may adequate , intravenous hydration may use Investigator ? discretion . ) Patients observe least 4 hour infusion Day 1 treatment course exclude immediate allergic reaction . Treatment may repeat maximum two additional course 4 week re-treatment criterion meet . At least three patient accrue dose level . Dose escalation within patient allow . PROJECTED ACCRUAL : Up 30 patient</detailed_description>
	<mesh_term>Immunotoxins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Disease Characteristics Histopathologic diagnosis one follow malignancy : ovarian carcinoma , nonmucinous epithelial histology , include primary peritoneal fallopian tube carcinoma ; malignant mesothelioma , except sarcomatous histology ; squamous cell cancer lung ; squamous cell cancer cervix ; squamous cell cancer head neck . Tissue block must available analysis . Tumor , initial recurrent , must positive ( least 30 % tumor cell ) mesothelin immunohistochemistry . Recurrent unresectable disease appropriate definitive therapy . At least 4 week elapse since prior therapy , recovery side effect . No concurrent antitumor treatment kind . Measurable evaluable tumor document within 4 week prior study entry . Patient Characteristics At least 18 year age . At least 12week life expectancy . Performance Status ( ECOG ) 02 . Adequate organ function , include : Absolute neutrophil count least 1,500/mm3 ; Platelets least 75,000/mm3 ; Creatinine , Calcium , total Bilirubin le equal upper limit normal ; Liver enzymes AST ALT less equal 2.5 x upper limit normal ; Albumin least 3.0 g/dL ; Oxygen ( O2 ) saturation 93 % ( room air ) . Informed Consent sign accordance institutional criterion . No known central nervous system ( CNS ) spinal cord involvement tumor . No detectable antibody SS1 ( dsFv ) PE38 . No concurrent antitumor therapy . No cardiovascular condition NY Heart Association Grade IIIV , clinicallysignificant pericardial effusion . No infection require parenteral antibiotic ; HIV infection ; seropositivity Hepatitis B Hepatitis C. Must pregnant nursing . Females childbearing potential must use effective method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>SS1 ( dsFv ) -PE38 Anti-Mesothelin Immunotoxin</keyword>
	<keyword>advanced malignancy</keyword>
</DOC>